Survival outcomes by cohort and mutational subgroups. Overall survival in (A) patients with vs without spliceosome mutations; (B) by specific spliceosome mutation; (C) in patients with co-occurring spliceosome and IDH1/2 mutations, wild-type patients with IDH1/2 mutations, and spliceosome patients without IDH1/2 mutations; and (D) in patients with co-occurring SRSF2 and IDH1/2 mutations, wild-type patients with IDH1/2 mutations, and SRSF2-mutated patients without IDH1/2 mutations.